Childhood leukemia is the most common cancer in children and adolescents, accounting for approximately one-third of all pediatric cancer cases globally. The emotional, financial, and physical toll on families and healthcare systems is significant. An estimated 58,785 new cases of childhood leukemia were diagnosed worldwide in 20211. In low- and middle-income countries (LMICs), including India, delayed diagnosis and limited access to specialized care significantly worsen outcomes, with survival rates often falling below 30 per cent, compared to 80 per cent in high-income countries.
Overview of types of childhood leukemia
Childhood leukemia is broadly classified into several types based on the type of blood cell affected.
• Acute Lymphocytic Leukemia (ALL) is the most common form, accounting for nearly 75-80 per cent of cases. It is characterized by the rapid proliferation of immature lymphoid cells.
• Acute Myeloid Leukemia (AML) is less common, comprising most of the remaining cases. It is generally associated with a greater treatment challenge and a worse prognosis than ALL.
• Other rare forms, including chronic leukemias and genetic subtypes, contribute to the complexity of diagnosis and management.
Why pediatric cancers require special attention
Children’s bodies and immune systems are still developing, making them uniquely vulnerable to the effects of cancer and its treatment. The psychosocial impact on families is profound, and the need for long-term follow-up care is critical and differs from adult cancers. Early intervention and specialised pediatric protocols have been instrumental in improving survival rates and quality of life for young patients.
Trends in survival rates over the past decades
The story of childhood leukemia treatment is one of remarkable progress. With advancements in chemotherapy, supportive care, bone marrow transplants, and newer targeted therapies, the survival rates have dramatically improved.
• For ALL, 5-year survival rates in high-income countries have soared from less than 10 per cent in the 1960s to over 90 per cent today.
• AML outcomes have also seen improvements, with 5-year survival rates for pediatric cases now ranging from 65 per cent to 70 per cent, though survival rates remain lower than for ALL.
These advancements highlight the importance of timely and appropriate treatment pathways.
The critical role of early detection
Despite the progress in treatment, a timely diagnosis remains a crucial factor. The symptoms of leukemia often mimic common childhood illnesses such as the flu, leading to dangerous delays. Recognising key warning signs is essential for parents, schools, and primary care providers. A routine complete blood count (CBC) test can often detect abnormalities that lead to a confirmed diagnosis through a bone marrow biopsy. Early diagnosis not only improves the chances of survival but also reduces the need for more aggressive treatments and their associated long-term side effects.
By understanding the nature of childhood leukemia, recognising its different types, and acknowledging both its global burden and the remarkable improvements in outcomes, one can fully appreciate the indispensable role that early detection plays. Continued awareness and access to specialised care are essential for enhancing survival rates and ensuring better long-term health and quality of life for affected children worldwide.
References: